# Lanreotide (Somatuline)

> Long-acting somatostatin analog for acromegaly and NETs.

Source: https://peptides.cafe/peptide/lanreotide
Category: Somatostatin Analog · Oncology
Tag: FDA-Approved · Endocrine

## Mechanism
Cyclic octapeptide somatostatin analog with high affinity for SSTR2 and SSTR5. Suppresses GH secretion and slows progression of gastroenteropancreatic neuroendocrine tumors.

## Research areas
- Acromegaly
- Gastroenteropancreatic NETs
- Carcinoid syndrome

## Common research protocols
- Depot: Deep subcutaneous 60–120 mg every 4 weeks.

## Study summaries
- "CLARINET trial" — NEJM (2014): Lanreotide significantly prolonged progression-free survival in enteropancreatic NETs.

## Considerations
- FDA-approved.
- Monitor gallbladder, glucose, and thyroid function.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.